Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

BG45, HDAC3 Inhibitor

BG45, HDAC3 Inhibitor

$59.00
A potent, selective and cell permeable HDAC3 inhibitor.
Catalog No. Unit Price Qty
M60266-2s 2 mg solid $59.00

Details

Product Information
Molecular Weight: 214.22
Formula: C11H10N4O
Purity: ≥98%
CAS#: 926259-99-6
Solubility: DMSO up to 100 mM
Chemical Name: N-(2-aminophenyl)pyrazine-2-carboxamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

BG45 is a potent, selective and cell permeable HDAC3 inhibitor. It inhibits HDAC3 with IC50 of 289 nM. It has IC50 of 2.0 µM, 2.2 µM and >20 µM for HDAC1, HDAC2, and HDAC6 in cell-free assays, respectively. BG45 triggers significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage. BG45 alone and in combination with bortezomib triggers significant tumor growth inhibition in vivo in a murine xenograft model of human MM.

How to Use:


In vitro:
BG45 was used at 10 µM final concentration in various in vitro assays.
In vivo: BG45 was dosed to mice bearing MM.1S xenograft by IP injection at 50 mg/kg (5 days a week), significantly inhibits MM tumor growth. (Formulation: 10% dimethylacetamide in 10% Kolliphor HS15 in PBS)

Reference:

  • 1. Minami J., et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. (2014) Leukemia. 28(3): 680-9. 

BG45_spec.pdf     
BG45_MSDS.pdf 


Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 214.22
Formula: C11H10N4O
Purity: ≥98%
CAS#: 926259-99-6
Solubility: DMSO up to 100 mM
Chemical Name: N-(2-aminophenyl)pyrazine-2-carboxamide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

BG45 is a potent, selective and cell permeable HDAC3 inhibitor. It inhibits HDAC3 with IC50 of 289 nM. It has IC50 of 2.0 µM, 2.2 µM and >20 µM for HDAC1, HDAC2, and HDAC6 in cell-free assays, respectively. BG45 triggers significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP-ribose) polymerase cleavage. BG45 alone and in combination with bortezomib triggers significant tumor growth inhibition in vivo in a murine xenograft model of human MM.

How to Use:


In vitro:
BG45 was used at 10 µM final concentration in various in vitro assays.
In vivo: BG45 was dosed to mice bearing MM.1S xenograft by IP injection at 50 mg/kg (5 days a week), significantly inhibits MM tumor growth. (Formulation: 10% dimethylacetamide in 10% Kolliphor HS15 in PBS)

Reference:

  • 1. Minami J., et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. (2014) Leukemia. 28(3): 680-9. 

BG45_spec.pdf     
BG45_MSDS.pdf 


Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: